Regulatory milestones

AMAG Pharmaceuticals Inc. (NASDAQ:AMAG) fell $3.53 (15%) to $19.96 on Tuesday after canceling a Sept. 22 presentation at the UBS Global Life Sciences Conference due to an upcoming meeting with FDA to discuss potential cardiac safety signals for Feraheme ferumoxytol injection (see B11).

Feraheme is an IV iron replacement therapy approved to treat iron deficiency anemia in chronic kidney disease (CKD) patients. The stock was off $5.25 (22%) to $18.24 for the week...